{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T11:59:57Z","timestamp":1773316797059,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T00:00:00Z","timestamp":1695600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Ziel der Arbeit<\/jats:title>\n                <jats:p>Analyse der H\u00e4ufigkeit einer zerebralen Amyloidangiopathie (CAA) bei Patient<jats:italic>inn<\/jats:italic>en mit kognitiven St\u00f6rungen und der H\u00e4ufigkeit einer Koinzidenz von gerinnungshemmender Therapie und CAA. Explorative Analyse von Zusammenh\u00e4ngen zwischen Antikoagulation und CAA-typischer L\u00e4sionslast in der MRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material und Methoden<\/jats:title>\n                <jats:p>Patient<jats:italic>inn<\/jats:italic>en mit subjektiver kognitiver St\u00f6rung (SCD), amnestischem und nichtamnestischem MCI (aMCI\/naMCI), Alzheimer-Demenz (AD), gemischter Demenz (MD) und vaskul\u00e4rer Demenz (VD) aus einem universit\u00e4ren Demenzzentrum, die sich von 02\/2016 bis 12\/2020 erstmals zur Demenzdiagnostik vorgestellt hatten, wurden in diese retrospektive Analyse eingeschlossen. Im Rahmen der Diagnostik erfolgten eine kranielle MRT inkl. Gradientenechosequenz und die Erfassung CAA-spezifischer MRT-Biomarker. Im Rahmen der retrospektiven Aktendurchsicht wurde das Vorliegen einer gerinnungshemmenden Medikation mit Thrombozytenaggregationshemmern, direkten oralen Antikoagulanzien (DOAK) oder Vitamin-K-Antagonisten zum Zeitpunkt der Vorstellung ermittelt.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Im Beobachtungszeitraum von 02\/2016 bis 12\/2020 wurden 458 Patient<jats:italic>inn<\/jats:italic>en (209 m\u00e4nnlich, 249 weiblich, Durchschnittsalter 73,2\u202f\u00b1\u20099,9\u00a0Jahre) mit SCD (<jats:italic>n<\/jats:italic>\u202f=\u200944), naMCI (<jats:italic>n<\/jats:italic>\u202f=\u200940), aMCI (<jats:italic>n<\/jats:italic>\u202f=\u2009182), AD (<jats:italic>n<\/jats:italic>\u202f=\u2009120), MD (<jats:italic>n<\/jats:italic>\u202f=\u200968) und VD (<jats:italic>n<\/jats:italic>\u202f=\u20094) analysiert. Bei 109 Patient<jats:italic>inn<\/jats:italic>en (23,8\u202f%) lagen die MR-Kriterien einer m\u00f6glichen oder wahrscheinlichen CAA vor. Die CAA-Pr\u00e4valenz war am h\u00f6chsten bei Patient<jats:italic>inn<\/jats:italic>en mit aMCI (39,4\u202f%) und MD (28,4\u202f%). Bei 30,3\u202f% der Patient<jats:italic>inn<\/jats:italic>en mit m\u00f6glicher oder wahrscheinlicher CAA bestand eine Thrombozytenaggregationshemmung, bei 12,8\u202f% eine DOAK-Therapie und bei 3,7\u202f% eine Therapie mit Vitamin-K-Antagonisten. Die Anzahl kortikaler und subkortikaler Mikroblutungen war insgesamt bei Patient<jats:italic>inn<\/jats:italic>en mit gerinnungshemmender Therapie h\u00f6her als bei Patient<jats:italic>inn<\/jats:italic>en ohne Gerinnungshemmung (<jats:italic>p<\/jats:italic>\u202f=\u20090,047). Ein Zusammenhang zwischen gerinnungshemmender Therapie und H\u00e4ufigkeit kortikaler superfizieller Siderosen bildete sich nicht ab (<jats:italic>p<\/jats:italic>\u202f=\u20090,634).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Die CAA ist bei Patient<jats:italic>inn<\/jats:italic>en mit kognitiven St\u00f6rungen h\u00e4ufig. Bei nahezu der H\u00e4lfte der Patient<jats:italic>inn<\/jats:italic>en mit CAA besteht eine gerinnungshemmende Medikation. Eine gerinnungshemmende Medikation ist mit einer gr\u00f6\u00dferen Anzahl kortikaler und subkortikaler Mikroblutungen vergesellschaftet.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00115-023-01547-8","type":"journal-article","created":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T14:02:30Z","timestamp":1695650550000},"page":"146-151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Analyse zur H\u00e4ufigkeit einer gerinnungshemmenden Medikation bei Patientinnen mit kognitiven St\u00f6rungen und zerebraler Amyloidangiopathie (CAA)","Analysis of the prevalence of anticoagulant therapy in patients with cognitive disorders and cerebral amyloid angiopathy (CAA)"],"prefix":"10.1007","volume":"95","author":[{"given":"R.","family":"Hau\u00dfmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Homeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hau\u00dfmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Linn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Donix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Puetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,25]]},"reference":[{"issue":"4","key":"1547_CR1","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00108-020-00747-7","volume":"61","author":"J Rother","year":"2020","unstructured":"Rother\u00a0J (2020) Stroke and intracerebral hemorrhage under anticoagulation or platelet inhibition\u2014when should treatment be restarted and how? Internist 61(4):424\u2013430","journal-title":"Internist"},{"issue":"6","key":"1547_CR2","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00115-021-01206-w","volume":"93","author":"R Haussmann","year":"2022","unstructured":"Haussmann\u00a0R et\u00a0al (2022) Intracerebral hemorrhage under platelet inhibition and oral anticoagulation in patients with cerebral amyloid angiopathy. Nervenarzt 93(6):599\u2013604","journal-title":"Nervenarzt"},{"issue":"11","key":"1547_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s11886-018-1052-1","volume":"20","author":"RJ Cannistraro","year":"2018","unstructured":"Cannistraro\u00a0RJ, Meschia\u00a0JF (2018) The clinical dilemma of anticoagulation use in patients with cerebral amyloid angiopathy and atrial fibrillation. Curr Cardiol Rep 20(11):106","journal-title":"Curr Cardiol Rep"},{"issue":"10","key":"1547_CR4","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1212\/WNL.32.10.1146","volume":"32","author":"CS Kase","year":"1982","unstructured":"Kase\u00a0CS et\u00a0al (1982) Lobar intracerebral hematomas: clinical and CT analysis of 22\u00a0cases. Neurology 32(10):1146\u20131150","journal-title":"Neurology"},{"issue":"12","key":"1547_CR5","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1212\/WNL.41.12.1881","volume":"41","author":"AR Massaro","year":"1991","unstructured":"Massaro\u00a0AR et\u00a0al (1991) Clinical discriminators of lobar and deep hemorrhages: the Stroke Data Bank. Neurology 41(12):1881\u20131885","journal-title":"Neurology"},{"issue":"8","key":"1547_CR6","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1212\/WNL.0b013e3181eee40f","volume":"75","author":"A Biffi","year":"2010","unstructured":"Biffi\u00a0A et\u00a0al (2010) Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology 75(8):693\u2013698","journal-title":"Neurology"},{"issue":"6","key":"1547_CR7","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1001\/archneurol.2009.42","volume":"66","author":"MW Vernooij","year":"2009","unstructured":"Vernooij\u00a0MW et\u00a0al (2009) Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol 66(6):714\u2013720","journal-title":"Arch Neurol"},{"issue":"15","key":"1547_CR8","doi-asserted-by":"publisher","first-page":"e016893","DOI":"10.1161\/JAHA.120.016893","volume":"9","author":"SP Ponamgi","year":"2020","unstructured":"Ponamgi\u00a0SP et al (2020) High mortality rates among patients with non-traumatic Intracerebral hemorrhage and atrial fibrillation on antithrombotic therapy are independent of the presence of cerebral Amyloid Angiopathy: insights from a\u00a0population-based study. J\u00a0Am Heart Assoc 9(15):e16893","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"1547_CR9","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1212\/WNL.55.7.947","volume":"55","author":"J Rosand","year":"2000","unstructured":"Rosand\u00a0J et al (2000) Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a\u00a0genetic and pathologic study. Neurology 55(7):947\u2013951","journal-title":"Neurology"},{"issue":"10","key":"1547_CR10","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.mayocp.2020.03.034","volume":"95","author":"R Ward","year":"2020","unstructured":"Ward\u00a0R et al (2020) Utility of HAS-BLED and CHA(2)DS(2)-VAsc scores among patients with atrial fibrillation and imaging evidence of cerebral amyloid angiopathy. Mayo Clin Proc 95(10):2090\u20132098","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"1547_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1161\/01.STR.26.8.1471","volume":"26","author":"RG Hart","year":"1995","unstructured":"Hart\u00a0RG, Boop\u00a0BS, Anderson\u00a0DC (1995) Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 26(8):1471\u20131477","journal-title":"Stroke"},{"issue":"2","key":"1547_CR12","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12975-020-00838-5","volume":"12","author":"M Schrag","year":"2021","unstructured":"Schrag\u00a0M et al (2021) Left atrial appendage closure for patients with cerebral amyloid angiopathy and atrial fibrillation: the LAA-CAA cohort. Transl Stroke Res 12(2):259\u2013265","journal-title":"Transl Stroke Res"},{"issue":"21","key":"1547_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January\u00a0CT et\u00a0al (2014) 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a\u00a0report of the American college of cardiology\/American heart association task force on practice guidelines and the heart rhythm society. J\u00a0Am Coll Cardiol 64(21):e1\u2013e76","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"1547_CR14","doi-asserted-by":"publisher","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","volume":"70","author":"VY Reddy","year":"2017","unstructured":"Reddy\u00a0VY et al (2017) 5\u2011year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J\u00a0Am Coll Cardiol 70(24):2964\u20132975","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"1547_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1136\/heartjnl-2016-309782","volume":"103","author":"S Sahay","year":"2017","unstructured":"Sahay\u00a0S et al (2017) Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a\u00a0network meta-analysis from randomised trials. Heart 103(2):139\u2013147","journal-title":"Heart"},{"issue":"1","key":"1547_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1161\/STROKEAHA.117.019409","volume":"49","author":"G Banerjee","year":"2018","unstructured":"Banerjee\u00a0G et\u00a0al (2018) Cognitive impairment before Intracerebral hemorrhage is associated with cerebral amyloid angiopathy. Stroke 49(1):40\u201345","journal-title":"Stroke"},{"issue":"5","key":"1547_CR17","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1212\/WNL.0000000000012234","volume":"97","author":"EE Smith","year":"2021","unstructured":"Smith\u00a0EE et al (2021) Cerebral amyloid angiopathy-related transient focal neurologic episodes. Neurology 97(5):231\u2013238","journal-title":"Neurology"},{"issue":"1","key":"1547_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1148\/radiol.2018170803","volume":"287","author":"S Haller","year":"2018","unstructured":"Haller\u00a0S et\u00a0al (2018) Cerebral microbleeds: imaging and clinical significance. Radiology 287(1):11\u201328","journal-title":"Radiology"},{"issue":"5","key":"1547_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eurpsy.2008.02.004","volume":"23","author":"K Abdulrab","year":"2008","unstructured":"Abdulrab\u00a0K, Heun\u00a0R (2008) Subjective Memory Impairment. A\u00a0review of its definitions indicates the need for a\u00a0comprehensive set of standardised and validated criteria. Eur Psychiatry 23(5):321\u2013330","journal-title":"Eur Psychiatry"},{"issue":"3","key":"1547_CR20","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1474-4422(19)30368-0","volume":"19","author":"F Jessen","year":"2020","unstructured":"Jessen\u00a0F et\u00a0al (2020) The characterisation of subjective cognitive decline. Lancet Neurol 19(3):271\u2013278","journal-title":"Lancet Neurol"},{"issue":"3","key":"1547_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert\u00a0MS et al (2011) The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement 7(3):270\u2013279","journal-title":"Alzheimers Dement"},{"issue":"3","key":"1547_CR22","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/j.1365-2796.2004.01388.x","volume":"256","author":"RC Petersen","year":"2004","unstructured":"Petersen\u00a0RC (2004) Mild cognitive impairment as a\u00a0diagnostic entity. J\u00a0Intern Med 256(3):183\u2013194","journal-title":"J Intern Med"},{"issue":"7","key":"1547_CR23","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1212\/WNL.34.7.939","volume":"34","author":"G McKhann","year":"1984","unstructured":"McKhann\u00a0G et al (1984) Clinical diagnosis of Alzheimer\u2019s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer\u2019s Disease. Neurology 34(7):939\u2013944","journal-title":"Neurology"},{"issue":"3","key":"1547_CR24","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0000000000000034","volume":"28","author":"P Sachdev","year":"2014","unstructured":"Sachdev\u00a0P et\u00a0al (2014) Diagnostic criteria for vascular cognitive disorders: a\u00a0VASCOG statement. Alzheimer Dis Assoc Disord 28(3):206\u2013218","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"1547_CR25","unstructured":"Jessen F, Spottke A (2016) S3-Leitline \u201eDemenzen\u201c. Deutsche Gesellschaft f\u00fcr Psychiatrieund Psychotherapie, Psychosomatik und Nervenheilkunde (DGPPN). https:\/\/register.awmf.org\/assets\/guidelines\/038-013l_S3-Demenzen-2016-07.pdf. Zugegriffen: 17.04.2023"},{"issue":"2","key":"1547_CR26","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1161\/STROKEAHA.117.016990","volume":"49","author":"SM Greenberg","year":"2018","unstructured":"Greenberg\u00a0SM, Charidimou\u00a0A (2018) Diagnosis of cerebral amyloid angiopathy: evolution of the boston criteria. Stroke 49(2):491\u2013497","journal-title":"Stroke"},{"issue":"4","key":"1547_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1212\/WNL.56.4.537","volume":"56","author":"KA Knudsen","year":"2001","unstructured":"Knudsen\u00a0KA et\u00a0al (2001) Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 56(4):537\u2013539","journal-title":"Neurology"},{"issue":"17","key":"1547_CR28","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1212\/WNL.0b013e3181dad605","volume":"74","author":"J Linn","year":"2010","unstructured":"Linn\u00a0J et\u00a0al (2010) Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 74(17):1346\u20131350","journal-title":"Neurology"},{"issue":"14","key":"1547_CR29","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1212\/WNL.0000000000003183","volume":"87","author":"D Wilson","year":"2016","unstructured":"Wilson\u00a0D et al (2016) Recurrent stroke risk and cerebral microbleed burden in ischemic stroke and TIA: a\u00a0meta-analysis. Neurology 87(14):1501\u20131510","journal-title":"Neurology"},{"issue":"2","key":"1547_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/ageing\/afaa275","volume":"50","author":"J Kelly","year":"2021","unstructured":"Kelly\u00a0J (2021) New horizons: managing antithrombotic dilemmas in patients with cerebral amyloid angiopathy. Age Ageing 50(2):347\u2013355","journal-title":"Age Ageing"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01547-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-023-01547-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-023-01547-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T13:04:37Z","timestamp":1707311077000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-023-01547-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,25]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["1547"],"URL":"https:\/\/doi.org\/10.1007\/s00115-023-01547-8","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,25]]},"assertion":[{"value":"11 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"R.\u00a0Hau\u00dfmann, P.\u00a0Homeyer, M.\u00a0Hau\u00dfmann, C.\u00a0Sauer, J.\u00a0Linn, M.\u00a0Donix, M.\u00a0Brandt und V.\u00a0Puetz geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}